Related Experiment Video

Updated: Jun 23, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Use of continuous insulin infusion pumps in young children with type 1 diabetes: a systematic review

Jeanne N Churchill, Rebekah L Ruppe, Arlene Smaldone

    Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners
    |April 30, 2009
    PubMed

    Insights

    Continuous subcutaneous insulin infusion (CSII) is safe and effective for young children with type 1 diabetes, improving glycemic control and quality of life. Highly motivated parents should consider CSII for their children.

    Area of Science:

    • Pediatric Endocrinology
    • Metabolic Disorders

    Background:

    • Insulin pump therapy (CSII) use is limited in young children due to hypoglycemia concerns.
    • Type 1 diabetes management in pediatric populations requires careful consideration of safety and efficacy.

    Purpose of the Study:

    • To evaluate the safety and efficacy of continuous subcutaneous insulin infusion (CSII) in young children (≤6 years) with type 1 diabetes.
    • To compare CSII with multiple-dose injection therapy in this age group.

    Main Methods:

    • Systematic review of clinical trials comparing CSII and multiple-dose injections in children 6 years or younger.
    • Primary outcomes included glycosylated hemoglobin (HbA1c) and hypoglycemic episodes.
    • Secondary outcomes assessed quality of life and parental satisfaction.

    Main Results:

    • Significant improvements in HbA1c were observed with CSII.
    • Trends indicated a decrease in hypoglycemic episodes.
    • Quality of life and parental satisfaction generally improved with CSII therapy.

    Conclusions:

    • Continuous subcutaneous insulin infusion (CSII) is a safe and effective insulin delivery method for young children with type 1 diabetes.
    • CSII should be considered for motivated parents managing type 1 diabetes in this age group.
    Abstract

    Related Concept Videos

    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    Insulin Formulations: Types and Delivery01:27

    Insulin Formulations: Types and Delivery

    Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
    Short-acting insulins are divided into rapid-acting...
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    Diabetes Mellitus: Overview and Type I Subtype01:22

    Diabetes Mellitus: Overview and Type I Subtype

    Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
    Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
    Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

    Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

    Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
    Type I Diabetes I: Introduction01:12

    Type I Diabetes I: Introduction

    Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...